Medicaid AMPs Exclude PBM Discounts Outside Of Mail Order – Final Rules
This article was originally published in The Pink Sheet Daily
Executive Summary
Citing potential antitrust violations and other concerns, CMS also narrows it definition for how sales of “authorized generics” are reported for average manufacturer prices.
You may also be interested in...
Pharmacy Groups File Suit To Stop New Medicaid Drug Payment System
Pharmacies could lose $8 billion over next five years if data used to set average manufacturer prices includes mail-order, clinic and physician sales, trade groups assert.
Pharmacy Groups File Suit To Stop New Medicaid Drug Payment System
Pharmacies could lose $8 billion over next five years if data used to set average manufacturer prices includes mail-order, clinic and physician sales, trade groups assert.
Medicaid AMP Rule Implementation Delay Requested By PhRMA, BIO, GPhA
Groups send joint letter to CMS urging delay in average manufacturer price methodology.